SAN DIEGO, Jan. 2, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), and Forge Therapeutics (Forge), announce today that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.
The US Food and Drug Administration (FDA) on Wednesday sought comments on a new effort to provide more clarity on the agency’s pharmaceutical application review and decision-making process.
Forge Therapeutics, Inc and Basilea Pharmaceutica International Ltd, a wholly-owned subsidiary of Basilea Pharmaceutica Ltd, have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. They will apply Forge's proprietary BLACKSMITH metalloenzyme chemistry platform to develop potent and selective inhibitors against two historically difficult-to-drug, unexploited antibiotic targets.
Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. They will apply Forge's proprietary BLACKSMITH metalloenzyme chemistry platform to develop potent and selective inhibitors against two historically difficult-to-drug, unexploited antibiotic targets.
Is now eligible to receive as much as $4 million in additional support to advance novel IV/Oral LpxC antibiotic. Forge Therapeutics, Inc., a biotechnology company developing medicines targeting metalloenzymes, has achieved technical milestones and received notice from CARB-X to proceed with the next stage of product funding for its novel IV/Oral LpxC antibiotic to treat urinary tract infections.
Forge Therapeutics has closed its first large round of financing, securing $15 million from MagnaSci Ventures, Evotec, and other investors. The tiny biotech firm, founded on technology developed in the labs of University of California, San Diego, chemist Seth Cohen, will use the proceeds to push forward its Gram-negative antibiotics program.
Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, and Active Motif, a leader in developing tools to enable epigenetics research, announced today a research collaboration aimed at advancing epigenetic research related to the family of iron-containing lysine demethylases known as Jumonji KDMs.